European Commission approves extension of the indication for Doptelet as treatment of ITP Jan. 21, 2021
Shanghai Jemincare Pharmaceuticals, Jiangxi Jemincare Group present factor XIa inhibitors Jan. 20, 2021
EdiGene obtains IND approval in China for ET-01 for transfusion dependent beta-thalassemia Jan. 18, 2021
Promising data presented from global phase III study with valoctocogene roxaparvovec in hemophilia A Jan. 12, 2021
Imara wraps up a phase IIa in sickle cell with mixed results Jan. 6, 2021 By Lee Landenberger Imara Inc. reported a mixed bag of phase IIa study data for its lead candidate, IMR-687, for treating sickle cell disease in adults, bringing an end to a study that the company found cumbersome and that eventually stung its stock.Read More
RSS
